Qu Biologics.png
Qu Biologics’ Immunomodulator Improves Fatty Liver Disease
06. Januar 2025 08:00 ET | Qu Biologics, Inc.
BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation...
FDA’s Approval of Br
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
14. März 2024 17:18 ET | Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...